Regenerative medicines company AVITA Medical (AVH:ASX) has reported a 46 per cent increase in revenue to $49.8 million for 2023. …
Investors back AVITA Medical after it reported full-year results
February 26, 2024 Australian Biotech
Latest Video
New Stories
-
La Trobe launches REACH program to fight antimicrobial resistance
May 6, 2026 - - Latest News -
If the imperative is international comparison, why limit it to these definitions?
May 5, 2026 - - Latest News -
Therapy funded three years after the 'clunky' and 'preventable deaths' admission
May 5, 2026 - - Latest News -
Time to make this 'targeted' consultation a little less targeted
May 5, 2026 - - Latest News -
Australia approves first in class therapy for chronic graft versus host disease
May 5, 2026 - - Latest News -
Lilly therapy approved in Australia as first non-covalent BTK inhibitor for common blood cancer
May 5, 2026 - - Latest News -
Medicines Australia calls for transparency, highlighting the risk of bias
May 5, 2026 - - Latest News